Biotech sector faces $170 billion patent cliff, drives precision oncology growth.

Monday, Jan 12, 2026 10:21 am ET1min read
ALLO--
CHRS--
ONCY--
PYXS--

The biotech sector is facing a patent cliff of $170 billion, prompting a shift towards late-stage oncology platforms with biologic-like manufacturing efficiency. Precision oncology is projected to reach $225.65 billion by 2032, driving investment in proprietary precision platforms like Oncolytics Biotech, Allogene Therapeutics, Coherus Oncology, Pyxis Oncology, and Enliven Therapeutics. Accelerated approval pathways for rare oncology indications are creating commercial opportunities.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet